Global Myocardial Infarction Pipeline Landscape 2025

DelveInsight's "Myocardial Infarction Pipeline Analysis 2025" delivers extensive intelligence on over 30 pharmaceutical firms and more than 40 investigational medications within the Myocardial Infarction development arena. The analysis encompasses profiles of Myocardial Infarction therapeutic candidates, spanning both clinical and preclinical phases. Additionally, it includes evaluation of Myocardial Infarction pipeline therapeutics by product category, developmental phase, administration method, and molecular classification. The report also spotlights dormant development programs in this therapeutic area.

Examine the comprehensive intelligence by DelveInsight and remain informed about the Myocardial Infarction Treatment Landscape @ Myocardial Infarction Pipeline Outlook

Primary Highlights from the Myocardial Infarction Pipeline Analysis

• On October 28, 2025, Boehringer Ingelheim initiated an investigation accessible to adults aged 18 and over who recently experienced a heart attack. The objective of this investigation is to determine whether a medication called BI 765845 helps individuals who have experienced a heart attack. The investigators also aim to test how effectively different doses of BI 765845 work and how they are tolerated by individuals who have experienced a heart attack.

• On October 1, 2025, Dong-A University revealed the EASTYLE trial will assess clinical benefit of step-down de-escalation DAPT strategy encompassing downgrading of P2Y12 inhibition (from 90 mg to 60 mg ticagrelor at 1 month post-PCI) and abbreviation of DAPT duration (aspirin discontinuation at 3 months post-PCI), relative to a conventional DAPT strategy in AMI patients. This trial will demonstrate that the optimal platelet inhibition would be attenuated over time even in AMI patients. The outcome will represent a significant advancement toward precision medicine in the field of antiplatelet treatment in AMI patients.

• DelveInsight's Myocardial Infarction pipeline analysis reveals a dynamic field featuring more than 30 engaged entities advancing over 40 investigational treatments for Myocardial Infarction management.

• Major Myocardial Infarction pharmaceutical firms include Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals, among additional organizations.

• Notable Myocardial Infarction Pipeline investigational medications include Ilomedin, MiSaver Registered, BI 765845, Empagliflozin, Tenecteplase, Clopidogrel, Enoxaparin, Eplerenone, among others.

Remain informed about the cutting-edge advancements in Myocardial Infarction treatments. Access updates and participate in the revolution in Cardiovascular Diseases Care @ Myocardial Infarction Clinical Trials Assessment

The Myocardial Infarction Pipeline Analysis delivers a condition synopsis, pipeline landscape, and therapeutic evaluation of principal investigational therapies within this domain. The analysis also emphasizes unaddressed medical requirements concerning Myocardial Infarction.

Myocardial Infarction Background

A myocardial infarction, commonly termed a heart attack, represents the irreversible necrosis of cardiac muscle resulting from prolonged ischemia, typically caused by a blockage in the arteries that supply blood to the heart. If a healthcare provider doesn't restore blood flow rapidly, a heart attack can cause permanent cardiac damage and death. The lack of blood flow can emerge due to numerous different factors but is typically related to a blockage in one or more of the coronary arteries. Treatment for a heart attack seeks to restore blood flow to the affected cardiac muscle as rapidly as possible, and it can involve various approaches, such as medication, percutaneous coronary intervention (PCI), and coronary artery bypass grafting. Several key factors influence the risk of experiencing a heart attack, including family history, high blood pressure, high cholesterol, and smoking.

Myocardial Infarction Investigational Drug Profiles

FDY 5301: Faraday Pharmaceuticals

FDY-5301 is an elemental reducing agent containing sodium iodide for which Faraday has secured a method of patent protection in major markets globally. Faraday has selected FDY-5301 for investigation based on the belief that its properties are uniquely well-suited to mitigate ischemia-reperfusion injury (IRI). In preclinical IRI models, FDY-5301 reduced tissue damage, infarct size, and inflammation. FDY-5301 functions as a catalytic neutralizer of hydrogen peroxide, a prominent reactive oxygen species implicated in the IRI cascade leading to cardiomyocyte death, and also acts as an immunomodulating agent. Presently, the medication is undergoing Phase III clinical trial assessment for AMI treatment.

Glenzocimab: Acticor Biotech

Glenzocimab is a humanized monoclonal antibody fragment engineered to target the human platelet glycoprotein VI (GPVI), which plays a crucial role in thrombus formation and stability. Its mechanism of action involves inhibiting platelet activation and aggregation, particularly in the context of ischemic stroke and myocardial infarction. Presently, it is undergoing Phase II clinical trial assessment for myocardial infarction management.

BI765845: Boehringer Ingelheim

BI765845 is an experimental medication created by Boehringer Ingelheim, classified as an anti-ischemic agent. It aims to address ischemic conditions by improving oxygen supply and reducing oxygen demand in affected tissues. Presently, the medication is undergoing Phase II clinical trial assessment for Myocardial infarction management.

Discover more about Myocardial Infarction therapeutic opportunities in our groundbreaking Myocardial Infarction research and development initiatives @ Myocardial Infarction Unmet Needs

The Myocardial Infarction Pipeline Analysis Offers Intelligence On

• The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Myocardial Infarction management, including cumulative therapies created by each organization for this indication.

• It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Myocardial Infarction Treatment.

• Myocardial Infarction pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.

• Myocardial Infarction investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.

• Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Myocardial Infarction market.

Myocardial Infarction Pharmaceutical Firms

Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals, among additional organizations.

The Myocardial Infarction pipeline analysis presents therapeutic evaluation of investigational medications by Administration Method. Products are classified under multiple administration routes including:

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Myocardial Infarction products are classified under various molecular categories including:

• Oligonucleotide

• Peptide

• Small molecule

Remain informed about how we're transforming the future of Cardiovascular Diseases @ Myocardial Infarction Market Drivers and Barriers, and Future Perspectives

Scope of the Myocardial Infarction Pipeline Analysis

• Coverage: Global

• Myocardial Infarction Pharmaceutical Firms: Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals, among additional organizations.

• Myocardial Infarction Pipeline Investigational Treatments: Ilomedin, MiSaver Registered, BI 765845, Empagliflozin, Tenecteplase, Clopidogrel, Enoxaparin, Eplerenone, among others.

• Myocardial Infarction Therapeutic Evaluation by Product Category: Monotherapy, Combination, Mono/Combination

• Myocardial Infarction Therapeutic Evaluation by Clinical Phases: Discovery, Preclinical, Phase I, Phase II, Phase III

For a comprehensive overview of our latest research findings and future plans, access the complete details of Myocardial Infarction Pipeline on our website @ Myocardial Infarction Emerging Drugs and Companies

Table of Contents

• Introduction

• Executive Summary

• Myocardial Infarction: Background

• Pipeline Therapeutics

• Therapeutic Evaluation

• Myocardial Infarction - DelveInsight's Analytical Perspective

• Late Phase Products (Phase III)

• FDY 5301: Faraday Pharmaceuticals

• Mid Phase Products (Phase II)

• Glenzocimab: Acticor Biotech

• Drug profiles in the comprehensive report.....

• Early Phase Products (Phase I)

• Drug Name: Company Name

• Mid Phase Products (Phase II)

• Preclinical Phase Products

• Drug Name: Company Name

• Inactive Products

• Myocardial Infarction - Collaborations Evaluation- Licensing / Partnering / Funding

• Myocardial Infarction - Unaddressed Medical Needs

• Myocardial Infarction - Market Drivers and Obstacles

• Appendix

About Us

DelveInsight is a premier healthcare-oriented market research and advisory organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and comprehensive knowledge of the life sciences and healthcare industries, we provide tailored research solutions and strategic insights to clients worldwide. Partner with us to obtain superior-quality, precise, and current intelligence to maintain competitive advantage.

Contact Us

Kanishk

kkumar@delveinsight.com